

# Anna Catania

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6348953/publications.pdf>

Version: 2024-02-01

97  
papers

4,593  
citations

94381

37  
h-index

106281

65  
g-index

98  
all docs

98  
docs citations

98  
times ranked

2846  
citing authors

#	ARTICLE	IF	CITATIONS
1	NDP-MSH treatment recovers marginal lungs during ex vivo lung perfusion (EVLN). <i>Peptides</i> , 2021, 141, 170552.	1.2	12
2	Activation of Melanocortin Receptors as a Potential Strategy to Reduce Local and Systemic Reactions Induced by Respiratory Viruses. <i>Frontiers in Endocrinology</i> , 2020, 11, 569241.	1.5	7
3	Multiple beneficial effects of melanocortin MC4 receptor agonists in experimental neurodegenerative disorders: Therapeutic perspectives. <i>Progress in Neurobiology</i> , 2017, 148, 40-56.	2.8	28
4	Î±-Melanocyte-stimulating-hormone (Î±-MSH) modulates human chondrocyte activation induced by proinflammatory cytokines. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 154.	0.8	16
5	Modulatory effects of NDP-MSH in the regenerating liver after partial hepatectomy in rats. <i>Peptides</i> , 2013, 50, 145-152.	1.2	13
6	Mechanisms of action of adrenocorticotrophic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 130-136.	1.4	78
7	Novel Î±-MSH Peptide Analogues with Broad Spectrum Antimicrobial Activity. <i>PLoS ONE</i> , 2013, 8, e61614.	1.1	35
8	Modulatory effects of NDP-MSH in the regenerating liver after partial hepatectomy in rats. <i>Peptides</i> , 2013, 50, 145-52.	1.2	4
9	Protective action of NDP-MSH in experimental subarachnoid hemorrhage. <i>Experimental Neurology</i> , 2012, 234, 230-238.	2.0	27
10	Molecular Changes Induced in Rat Liver by Hemorrhage and Effects of Melanocortin Treatment. <i>Anesthesiology</i> , 2012, 116, 692-700.	1.3	10
11	Treatment of Infantile Spasms. <i>Journal of Child Neurology</i> , 2011, 26, 1411-1421.	0.7	63
12	The Melanocortin System in Control of Inflammation. <i>Scientific World Journal</i> , The, 2010, 10, 1840-1853.	0.8	140
13	The peptide NDP-MSH induces phenotype changes in the heart that resemble ischemic preconditioning. <i>Peptides</i> , 2010, 31, 116-122.	1.2	25
14	Protective Effects of Melanocortins in Systemic Host Reactions. <i>Advances in Experimental Medicine and Biology</i> , 2010, 681, 117-125.	0.8	10
15	Antimicrobial properties of melanocortins: comment to the manuscript "Anti-Candida activity of Î±-melanocyte-stimulating hormone (Î±-MSH) peptides" by Isabella Rauch et al.. <i>Journal of Leukocyte Biology</i> , 2009, 85, 373-373.	1.5	1
16	Detrimental consequences of brain injury on peripheral cells. <i>Brain, Behavior, and Immunity</i> , 2009, 23, 877-884.	2.0	86
17	Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells. <i>Arthritis Research and Therapy</i> , 2009, 11, R151.	1.6	22
18	Identification of Potential Therapeutic Targets in Malignant Mesothelioma Using Cell-Cycle Gene Expression Analysis. <i>American Journal of Pathology</i> , 2009, 174, 762-770.	1.9	48

#	ARTICLE	IF	CITATIONS
19	Î±-Melanocyte Stimulating Hormone in Critically Injured Trauma Patients. <i>Journal of Trauma</i> , 2009, 66, 465-469.	2.3	8
20	Neuroprotective actions of melanocortins: a therapeutic opportunity. <i>Trends in Neurosciences</i> , 2008, 31, 353-360.	4.2	123
21	Treatment with Î±-melanocyte stimulating hormone preserves calcium regulatory proteins in rat heart allografts. <i>Brain, Behavior, and Immunity</i> , 2008, 22, 817-823.	2.0	13
22	The melanocortin system in leukocyte biology. <i>Journal of Leukocyte Biology</i> , 2007, 81, 383-392.	1.5	85
23	PRODUCTION AND EFFECTS OF Î±-MELANOCYTE-STIMULATING HORMONE DURING ACUTE LUNG INJURY. <i>Shock</i> , 2007, 27, 326-333.	1.0	23
24	The synthetic melanocortin (CKPV)2 exerts broad anti-inflammatory effects in human neutrophils. <i>Peptides</i> , 2007, 28, 2016-2022.	1.2	19
25	Structure-function Relationships and Conformational Properties of Î±-MSH(6-13) Analogues with Candidacidal Activity. <i>Chemical Biology and Drug Design</i> , 2007, 69, 68-74.	1.5	12
26	Inhibitory Effects of the Peptide (CKPV)2 on Endotoxin-Induced Host Reactions. <i>Journal of Surgical Research</i> , 2006, 131, 209-214.	0.8	17
27	Alteration in the Transcriptional Profile of Livers from Brain-dead Organ Donors. <i>Transplantation</i> , 2006, 82, 69-79.	0.5	20
28	Callipeltins: new antifungal peptides from the marine sponge <i>Latrunculia</i> sp.. <i>Tetrahedron</i> , 2006, 62, 833-840.	1.0	46
29	Reduced Expression of the Melanocortin-1 Receptor in Human Liver during Brain Death. <i>NeuroImmunoModulation</i> , 2006, 13, 51-55.	0.9	19
30	Gene Expression Profiling Reveals Multiple Protective Influences of the Peptide Î±-Melanocyte-Stimulating Hormone in Experimental Heart Transplantation. <i>Journal of Immunology</i> , 2005, 175, 3391-3401.	0.4	23
31	Design and Synthesis of Melanocortin Peptides with Candidacidal and Anti-TNF-Î± Properties. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 1384-1388.	2.9	18
32	Autocrine inhibitory influences of Î±-melanocyte-stimulating hormone in malignant pleural mesothelioma. <i>Journal of Leukocyte Biology</i> , 2004, 75, 253-259.	1.5	11
33	Targeting Melanocortin Receptors as a Novel Strategy to Control Inflammation. <i>Pharmacological Reviews</i> , 2004, 56, 1-29.	7.1	397
34	Volume-regulated Cl <sup>-</sup> channels in human pleural mesothelioma cells. <i>FEBS Letters</i> , 2004, 559, 45-50.	1.3	17
35	Changes in viremia and circulating interferon-Î± during hemodialysis in hepatitis C virus-positive patients: only coincidental phenomena?. <i>American Journal of Kidney Diseases</i> , 2003, 42, 143-150.	2.1	60
36	Novel Î±-Melanocyte Stimulating Hormone Peptide Analogues with High Candidacidal Activity. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 850-855.	2.9	30

#	ARTICLE	IF	CITATIONS
37	$\alpha$ -Melanocyte-Stimulating Hormone Is Decreased in Plasma of Patients with Acute Brain Injury. Journal of Neurotrauma, 2003, 20, 251-260.	1.7	37
38	Alpha-melanocyte stimulating hormone in modulation of inflammatory reactions. Pediatric Endocrinology Reviews, 2003, 1, 101-8.	1.2	11
39	Anti-Inflammatory Effects of $\alpha$ -Melanocyte-Stimulating Hormone in Celiac Intestinal Mucosa. NeuroImmunoModulation, 2002, 10, 208-216.	0.9	27
40	$\alpha$ -Melanocyte-stimulating hormone protects the allograft in experimental heart transplantation. Transplantation, 2002, 74, 1678-1684.	0.5	42
41	Antimicrobial effects of $\alpha$ -MSH peptides. Journal of Leukocyte Biology, 2000, 67, 233-239.	1.5	134
42	Plasma concentrations of $\alpha$ -melanocyte-stimulating hormone are elevated in patients on chronic haemodialysis. Nephrology Dialysis Transplantation, 2000, 15, 1212-1216.	0.4	26
43	Plasma concentrations and anti-L-cytokine effects of $\alpha$ -melanocyte stimulating hormone in septic patients. Critical Care Medicine, 2000, 28, 1403-1407.	0.4	42
44	The human astrocytoma cell line U373MG produces monocyte chemotactic protein (MCP)-1 upon stimulation with $\alpha$ -amyloid protein. Neuroscience Letters, 2000, 283, 177-180.	1.0	48
45	$\alpha$ -Melanocyte-stimulating Hormone in Normal Human Physiology and Disease States. Trends in Endocrinology and Metabolism, 2000, 11, 304-308.	3.1	69
46	The Neuroimmunomodulatory Peptide $\alpha$ -MSH. Annals of the New York Academy of Sciences, 2000, 917, 221-226.	1.8	28
47	The Neuropeptide $\alpha$ -MSH in Host Defense. Annals of the New York Academy of Sciences, 2000, 917, 227-231.	1.8	37
48	Inhibition of Systemic Inflammation by Central Action of the Neuropeptide $\alpha$ -Melanocyte-Stimulating Hormone. NeuroImmunoModulation, 1999, 6, 187-192.	0.9	44
49	Inhibition of peripheral NF- $\kappa$ B activation by central action of $\alpha$ -melanocyte-stimulating hormone. Journal of Neuroimmunology, 1999, 99, 211-217.	1.1	75
50	Elevated concentrations of plasma $\alpha$ -melanocyte stimulating hormone are associated with reduced disease progression in HIV-infected patients. Translational Research, 1999, 133, 309-315.	2.4	14
51	Systemically administered $\alpha$ -melanocyte-stimulating peptides inhibit NF- $\kappa$ B activation in experimental brain inflammation. Brain Research, 1999, 836, 31-37.	1.1	71
52	Autocrine $\alpha$ -melanocyte-stimulating hormone inhibits NF- $\kappa$ B activation in human glioma. Journal of Neuroscience Research, 1999, 58, 684-689.	1.3	36
53	$\alpha$ -Melanocyte-Stimulating Hormone Inhibits NF- $\kappa$ B Activation and I $\kappa$ B Degradation in Human Glioma Cells and in Experimental Brain Inflammation. Experimental Neurology, 1999, 157, 359-365.	2.0	78
54	$\alpha$ -MSH Peptides Inhibit Production of Nitric Oxide and Tumor Necrosis Factor- $\alpha$ by Microglial Cells Activated with $\beta$ -Amyloid and Interferon $\gamma$ . Biochemical and Biophysical Research Communications, 1999, 263, 251-256.	1.0	85

#	ARTICLE	IF	CITATIONS
55	Î±-MSH in Systemic Inflammation: Central and Peripheral Actions. Annals of the New York Academy of Sciences, 1999, 885, 183-187.	1.8	30
56	Mechanisms of Antiinflammatory Action of the Neuroimmunomodulatory Peptide Î±-MSH. Annals of the New York Academy of Sciences, 1998, 840, 373-380.	1.8	69
57	The Neuropeptide Î±-MSH in HIV Infection and Other Disorders in Humans. Annals of the New York Academy of Sciences, 1998, 840, 848-856.	1.8	27
58	Melanocortin peptides inhibit production of proinflammatory cytokines in blood of HIV-infected patients. Peptides, 1998, 19, 1099-1104.	1.2	28
59	WITHIN-PATIENT VARIABILITY OF HORMONE AND CYTOKINE CONCENTRATIONS IN HEART FAILURE. Pharmacological Research, 1998, 37, 213-217.	3.1	25
60	Peptide Modulation of Inflammatory Processes within the Brain. NeuroImmunoModulation, 1998, 5, 178-183.	0.9	29
61	Melanocortin peptides inhibit production of proinflammatory cytokines and nitric oxide by activated microglia. Journal of Leukocyte Biology, 1998, 63, 740-745.	1.5	142
62	The Anticytokine Peptide, $\alpha$ -MSH, in Infectious and Inflammatory Disorders. , 1998, , .		0
63	A Potential Mechanism of Local Anti-Inflammatory Action of Alpha-Melanocyte-Stimulating Hormone within the Brain: Modulation of Tumor Necrosis Factor-Alpha Production by Human Astrocytic Cells. NeuroImmunoModulation, 1997, 4, 37-41.	0.9	75
64	Î±-MSH Modulates Experimental Inflammatory Bowel Disease. Peptides, 1997, 18, 381-385.	1.2	94
65	Anti-inflammatory actions of the neuroimmunomodulator Î±-MSH. Trends in Immunology, 1997, 18, 140-145.	7.5	376
66	The neuropeptide Î±-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro. Peptides, 1996, 17, 675-679.	1.2	197
67	Endotoxin Causes Release of Î±-Melanocyte-Stimulating Hormone in Normal Human Subjects. NeuroImmunoModulation, 1995, 2, 258-262.	0.9	40
68	Endogenous cytokine antagonists during myocardial ischemia and thrombolytic therapy. American Heart Journal, 1995, 130, 204-211.	1.2	44
69	The Anticytokine Neuropeptide Î±-Melanocyte-Stimulating Hormone in Synovial Fluid of Patients with Rheumatic Diseases: Comparisons with Other Anticytokine Molecules. NeuroImmunoModulation, 1994, 1, 321-328.	0.9	48
70	Binding of Anti-Inflammatory Î±-Melanocyte-Stimulating-Hormone Peptides and Proinflammatory Cytokines to Receptors on Melanoma Cells. NeuroImmunoModulation, 1994, 1, 121-126.	0.9	17
71	The Neuropeptide Alpha-Melanocyte-Stimulating Hormone Inhibits Experimental Arthritis in Rats. NeuroImmunoModulation, 1994, 1, 28-32.	0.9	102
72	Central Neurogenic Antiinflammatory Action of Î±-MSH: Modulation of Peripheral Inflammation Induced by Cytokines and Other Mediators of Inflammation. Neuroendocrinology, 1994, 59, 138-143.	1.2	89

#	ARTICLE	IF	CITATIONS
73	Cytokine Antagonists in Infectious and Inflammatory Disorders. <i>Annals of the New York Academy of Sciences</i> , 1994, 741, 149-161.	1.8	16
74	Plasma Concentration of Cytokine Antagonists in Patients with HIV Infection. <i>NeuroImmunoModulation</i> , 1994, 1, 42-49.	0.9	22
75	The Neuropeptide Alpha-Melanocyte-Stimulating Hormone: A Key Component Neuroimmunomodulation. <i>NeuroImmunoModulation</i> , 1994, 1, 93-99.	0.9	42
76	Proopiomelanocortin-Derived Peptides and Cytokines: Relations in Patients with Acquired Immunodeficiency Syndrome. <i>Clinical Immunology and Immunopathology</i> , 1993, 66, 73-79.	2.1	34
77	Inhibition of IL-1 $\beta$ -induced peripheral inflammation by peripheral and central administration of analogs of the neuropeptide $\beta$ -MSH. <i>Brain Research Bulletin</i> , 1993, 32, 311-314.	1.4	56
78	$\beta$ -Melanocyte-Stimulating Hormone Peptides in Host Responses From Basic Evidence to Human Research. <i>Annals of the New York Academy of Sciences</i> , 1993, 680, 412-423.	1.8	26
79	$\beta$ -Melanocyte Stimulating Hormone in the Modulation of Host Reactions*. <i>Endocrine Reviews</i> , 1993, 14, 564-576.	8.9	132
80	Pyrogenic and Inflammatory Actions of Cytokines and Their Modulation by Neuropeptides: Techniques and Interpretations. <i>Methods in Neurosciences</i> , 1993, 17, 61-77.	0.5	13
81	Scintigraphic Study of Extra-adrenal Ganglioneuroma in a Patient with Overlap between Multiple Endocrine Neoplasia Types 1 and 2. <i>Clinical Nuclear Medicine</i> , 1992, 17, 573-576.	0.7	3
82	The neuropeptide $\beta$ -MSH in control of fever. <i>Pharmacological Research</i> , 1992, 26, 72-73.	3.1	2
83	$\beta$ -MSH peptides inhibit acute inflammation induced in mice by rIL-1 $\beta$ , rIL-6, rTNF- $\beta$ and endogenous pyrogen but not that caused by LTB <sub>4</sub> , PAF and rIL-8. <i>Cytokine</i> , 1992, 4, 320-328.	1.4	74
84	Central administration of the peptide $\beta$ -MSH inhibits inflammation in the skin. <i>Peptides</i> , 1991, 12, 795-798.	1.2	82
85	Dexamethasone facilitates release of the neuropeptide $\beta$ -MSH. <i>Brain Research Bulletin</i> , 1991, 26, 727-730.	1.4	9
86	Clinical experience with the adrenal scanning agents iodine 131-19-iodocholesterol and selenium 75-6-selenomethylcholesterol. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1991, 18, 817-23.	2.2	8
87	Evidence for an Impairment of the Immune-Adrenal Circuit in Patients with Acquired Immunodeficiency Syndrome. <i>Hormone and Metabolic Research</i> , 1990, 22, 597-598.	0.7	6
88	Hormonal Response During Antigenic Challenge in Normal Subjects. <i>International Journal of Neuroscience</i> , 1990, 51, 295-296.	0.8	9
89	Administration of gonadotropin-releasing hormone analog as adjunctive therapy in women systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1989, 32, 1186-1188.	6.7	15
90	Cushing's Syndrome due to Unilateral Adrenal Nodular Hyperplasia with Incomplete Inhibition of the Contralateral Gland. <i>Hormone Research</i> , 1986, 23, 9-15.	1.8	10

#	ARTICLE	IF	CITATIONS
91	EVIDENCE FOR DIFFERING DOPAMINERGIC ACTIVITY IN CHILDHOODâ€•OR ADULTâ€•ONSET OBESITY. <i>Clinical Endocrinology</i> , 1985, 22, 75-81.	1.2	7
92	SOLITARY THYROID NODULES. <i>Lancet, The</i> , 1985, 326, 1237.	6.3	1
93	Corticotropin releasing factor stimulates cAMP formation in pituitary corticotropic tumor cells. <i>Life Sciences</i> , 1984, 34, 359-363.	2.0	2
94	Plasma ACTH-response to the corticotropin releasing factor in patients with Cushing's disease. Comparison with the lysine-vasopressin test. <i>Metabolism: Clinical and Experimental</i> , 1984, 33, 478-481.	1.5	23
95	Gonadotropin response to gonadotropin releasing hormone in acute schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1984, 8, 411-417.	2.5	6
96	Inhibitory effect of calcitonin on growth hormone and insulin secretion in man. <i>Metabolism: Clinical and Experimental</i> , 1978, 27, 987-992.	1.5	72
97	PLASMA PROLACTIN RESPONSE TO LUTEINIZING HORMONE RELEASING HORMONE IN ACROMEGALIC PATIENTS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1976, 43, 689-691.	1.8	21